What’s the closest thing to investing in a private equity healthcare fund, where a few big winners can make us forget that the rest were even stocks we owned? I’d argue it is a pair of biotech ETFs that spread their risk, but not too much, while offering a piece of the next generation of medical advances.
Here’s a summary table which includes that pair of forward-looking, upwardly mobile ETFs, as well as the largest ETF in the biotech industry.
